News | June 04, 2010

Transcatheter Aortic Valve Shows Positive One-Year Outcomes

June 4, 2010 – One-year mortality rates were very low for 1,038 high-risk patients, many of whom were too sick to undergo traditional open-heart surgery, who received the Sapien transcatheter heart valve. Results of the SOURCE Registry were presented last week at EuroPCR in Paris.

The registry is the largest reported experience in the world with one-year adjudicated data on consecutive patients treated with transcatheter heart valves. It showed a one-year survival rate of 81.1 percent in transfemoral procedures (valve delivered via the femoral artery) and 72.1 percent in transapical procedures (valve delivered via a small incision through the ribs).

"The encouraging outcomes add to the evolving body of clinical evidence that demonstrates transcatheter aortic valve implantation is a viable option for this high-risk patient population. The data provide valuable, real world insights that enable the continued advancement of this important treatment for patients in need of alternative therapies to traditional open-heart surgery," said Martyn Thomas, M.D., director of cardiothoracic services, Guys and St. Thomas' National Health Service (NHS) Foundation Trust in London.

The SOURCE Registry includes outcomes data from 100 percent of patients treated with the Edwards Sapien transcatheter heart valve at 32 European centers from November 2007 to January 2009 in its initial Cohort I. One year follow-up data was obtained on 98 percent of studied patients. Thomas also announced that 30-day results on an additional cohort of 1,301 patients (Cohort 2) enrolled in 2009 will be reported in the fall.

"The SOURCE Registry is unprecedented in its rigor as a commercial registry, which is critical for our understanding of the developing therapy of transcatheter aortic valve implantation. The one-year outcomes continue to demonstrate that European clinical teams are translating early clinical learnings into successful therapy in an appropriate patient population," said Olaf Wendler, M.D., Ph.D., clinical director for cardiology and cardiothoracic surgery, King's College Hospital in London.

Thomas and Wendler provide paid consulting services to Edwards for education, and research and development of transcatheter valve technologies.

For more information: www.edwards.com

Related Content

Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study| August 16, 2017
Aug. 16, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking Clinic
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System
News | Heart Valve Technology| August 09, 2017
Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-...
Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems| August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
Overlay Init